In the pivotal Phase 3 TRANSFORM trial, single
infusion of Breyanzi significantly outperformed the nearly 30-year
standard of care with median event-free survival of 10.1 months vs.
2.3 months and a well-established safety profile
Approval was also based on data from the Phase
2 PILOT study, the first and only company-sponsored study of a CAR
T cell therapy in patients with primary refractory or relapsed LBCL
who are not considered candidates for transplant, in which Breyanzi
delivered deep and durable responses
With this approval, Breyanzi now has the
broadest patient eligibility of any CAR T cell therapy in relapsed
or refractory LBCL, reinforcing company’s leadership in delivering
innovative cancer treatments with Breyanzi as a cornerstone of its
diversified cell therapy portfolio and pipeline
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S.
Food and Drug Administration (FDA) has approved Breyanzi®
(lisocabtagene maraleucel), a CD19-directed chimeric antigen
receptor (CAR) T cell therapy, for the treatment of adult patients
with large B-cell lymphoma (LBCL), including diffuse large B-cell
lymphoma (DLBCL) not otherwise specified (including DLBCL arising
from indolent lymphoma), high-grade B-cell lymphoma, primary
mediastinal large B-cell lymphoma, and follicular lymphoma grade
3B, who have:
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220427005982/en/
Product image for download (Photo:
Bristol Myers Squibb)
- Refractory disease to first-line chemoimmunotherapy or relapse
within 12 months of first-line chemoimmunotherapy; or
- Refractory disease to first-line chemoimmunotherapy or relapse
after first-line chemoimmunotherapy and are not eligible for
hematopoietic stem cell transplant (HSCT) due to comorbidities or
age.
With these two new indications, Breyanzi now has the broadest
patient eligibility of any CAR T cell therapy in relapsed or
refractory LBCL. Breyanzi is not indicated for the treatment of
patients with primary central nervous system lymphoma. Please see
the Important Safety Information section below, including Boxed
WARNINGS for Breyanzi regarding cytokine release syndrome (CRS)
and neurologic toxicities.
Breyanzi has demonstrated clinically meaningful and
statistically significant improvements in event-free survival
(EFS), complete responses (CR) and progression-free survival (PFS)
compared to standard therapy in patients with LBCL that is primary
refractory or relapsed within 12 months after first-line therapy.
An improvement in EFS represents an increase in the length of time
in which patients are alive and without disease progression or in
need of further treatment. Breyanzi, a differentiated CAR T cell
therapy, is made from a patient’s own T cells, which are collected
and genetically reengineered to become CAR T cells that are then
delivered via infusion as a one-time treatment. Breyanzi can be
administered in the inpatient or outpatient setting at a certified
treatment center.
“As part of our commitment to developing innovative cancer
treatments for patients with critical unmet need, Breyanzi offers a
potentially curative option for more patients,” said Ester Banque,
senior vice president & general manager, U.S. Hematology,
Bristol Myers Squibb. “Based on the demonstrated clinical benefit,
this approval of Breyanzi underscores the significant advances we
are making to deliver on the promise of cell therapy.”
LBCL is a difficult-to-treat and aggressive blood cancer, and up
to 40% of patients have disease that is refractory to or relapses
after initial therapy. Historically, the only potential cure for
these patients is the current standard of care consisting of
intensive hospital-based salvage immunochemotherapy followed by
high-dose chemotherapy and HSCT in those whose disease responds to
the salvage therapy. However, half of patients are not considered
candidates for a stem cell transplant due to age and/or
comorbidities, and only an estimated 25% of those who are
candidates are able to receive a stem cell transplant and
experience long-term clinical benefit. For patients who are not
considered candidates for stem cell transplant, treatment options
are limited. If left untreated, relapsed or refractory LBCL has a
life expectancy of just three to four months.
“Breyanzi represents a remarkable advance over a nearly 30-year
standard of care, providing significantly improved efficacy with a
well-established safety profile,” said Manali Kamdar, M.D., lead
investigator of the TRANSFORM study and Associate Professor,
Clinical Director of Lymphoma Services, Division of Hematology,
Hematologic Malignancies and Stem Cell Transplantation, University
of Colorado Cancer Center. “This important milestone reinforces the
benefit of offering a CAR T cell therapy option to patients earlier
in their treatment journey and it’s critical that we begin the work
to implement this therapy into standard practice as a second-line
treatment in order to help improve outcomes for more patients.”
“Patients with large B-cell lymphoma whose disease does not
respond to or relapses after first-line therapy often face lengthy
and intensive cycles of chemotherapy with the goal of proceeding to
stem cell transplant,” said Lee Greenberger, Ph.D., Chief
Scientific Officer of the Leukemia & Lymphoma Society (LLS).
“As one of the earliest supporters of CAR T since the 1990’s, LLS
is excited to see the FDA approval of a CD19 CAR T cell therapy
that has moved from later lines of therapy to a second-line option,
which offers patients with relapsed or refractory large B-cell
lymphoma the potential for long-term remission and the hope of a
cure.”
Breyanzi is the only CAR T cell therapy that has been evaluated
in a broad second-line patient population for LBCL in two distinct
company-sponsored studies, including in patients whose disease
relapsed within or later than 12 months following first-line
treatment and regardless of transplant candidacy.
The approval of the expanded indications for Breyanzi is based
on results from the pivotal Phase 3 TRANSFORM study in which adults
with LBCL that was primary refractory or relapsed within 12 months
of front-line therapy were randomized to receive Breyanzi or
standard therapy consisting of salvage immunochemotherapy, and if
responsive, high-dose chemotherapy and HSCT. The trial included
patients with diverse histologic subtypes and high-risk features,
and offered a patient-centric design, allowing for bridging
immunochemotherapy in the Breyanzi arm for disease control, which
reflects real-world clinical practice and allowed for inclusion of
patients with more aggressive and fast-progressing disease. Due to
the high rate of patients whose disease does not respond to salvage
immunochemotherapy, the trial also allowed for crossover from the
standard therapy arm to the Breyanzi arm if patients did not derive
a response after three cycles of salvage chemotherapy or had
disease progression at any time.
Results from the TRANSFORM study showed, Breyanzi (n=92) more
than quadrupled median EFS compared to standard therapy (n=92)
(10.1 months vs. 2.3 months [HR: 0.34; 95% CI (0.22-0.52)
p<0.0001]). The majority of patients achieved a CR with Breyanzi
compared to less than half with standard therapy (66% [95% CI: 56%
- 76%] vs. 39% [95% CI: 29% - 50%]; p<0.0001), with median
duration of CR not reached in the Breyanzi arm (95% CI: 7.9-NR).
Results also showed Breyanzi more than doubled PFS versus standard
therapy (median PFS: 14.8 months vs. 5.7 months [HR: 0.41; 95% CI:
0.25-0.66; p=0.0001]). In the study, nearly all patients (97%) in
the Breyanzi arm received treatment versus less than half (47%) of
patients who completed high-dose chemotherapy and autologous HSCT
in the standard therapy arm.
The efficacy of Breyanzi in the second-line setting was also
based on data from the Phase 2 PILOT study, in which 61 adults with
primary refractory or relapsed LBCL who were not considered
candidates for stem cell transplant were treated with Breyanzi. The
PILOT study enrolled a broad patient population based on age,
performance status and/or organ function and comorbidities, and
regardless of time to relapse following first-line treatment.
Breyanzi showed deep and durable responses, with an overall
response rate of 80%, the study’s primary endpoint, and a CR rate
of 54%, with median time to CR of one month (range: 0.8 – 6.9
months). Median duration of response was 11.2 months, with the
median duration of response not reached for those patients who
achieved a CR.
Breyanzi has a well-established safety profile and based on
results from the TRANSFORM and PILOT studies, occurrences of CRS
and neurologic events were generally low grade and mostly resolved
quickly with standard protocols, and without the use of
prophylactic steroids. Any-grade CRS was reported in less than half
of patients (45%; 68/150), with Grade 3 CRS reported in 1.3% of
patients. Any-grade neurologic events were reported in 27% (41/150)
of patients treated with Breyanzi, with Grade 3 neurologic events
reported in 7% of patients. Median time to onset of CRS was four
days (range: 1 to 63 days) and median duration of CRS was four days
(range: 1 to 16 days). The median time to onset of neurologic
events was eight days (range: 1 to 63 days). The median duration of
neurologic toxicities was six days (range: 1 to 119 days). The
delayed onset of CRS and neurologic events allowed for the option
of outpatient treatment and management of patients. In addition,
the clinical profile of Breyanzi supported its use in a broad range
of relapsed or refractory LBCL patients.
Breyanzi is broadly covered by commercial and government
insurance programs in the U.S.
About Breyanzi
Breyanzi is a CD-19 directed chimeric antigen receptor (CAR) T
cell therapy, administered as a defined composition to reduce
variability of the CD8 and CD4 component dose. Breyanzi has a 4-1BB
costimulatory domain which enhances the expansion and persistence
of the CAR T cells. Breyanzi was previously approved by the U.S.
Food and Drug Administration for the treatment of adult patients
with relapsed or refractory LBCL after two or more lines of
systemic therapy, including diffuse large B-cell lymphoma (DLBCL)
not otherwise specified (including DLBCL arising from indolent
lymphoma), high-grade B-cell lymphoma, primary mediastinal large
B-cell lymphoma, and follicular lymphoma grade 3B. Breyanzi is
available only through a restricted program under a Risk Evaluation
and Mitigation Strategy (REMS) called the BREYANZI REMS.
Breyanzi is also approved in Europe, Switzerland, Canada and
Japan for relapsed and refractory LBCL after two or more lines of
systemic therapy. Bristol Myers Squibb’s clinical development
program for Breyanzi includes clinical studies in earlier lines of
treatment for patients with relapsed or refractory LBCL and other
types of lymphoma. For more information, visit
clinicaltrials.gov.
About TRANSFORM
TRANSFORM (NCT03575351) is a pivotal, global, randomized,
multicenter Phase 3 trial evaluating Breyanzi compared to current
standard therapy regimens (platinum-based salvage chemotherapy
followed by high-dose chemotherapy and HSCT in patients responding
to salvage chemotherapy) in patients with large B-cell lymphoma
that was primary refractory or relapsed within 12 months after
CD20-antibody and anthracycline containing first-line therapy.
Patients were randomized to receive Breyanzi or standard of care
salvage therapy, including rituximab plus dexamethasone, high-dose
cytarabine, and cisplatin (R-DHAP), rituximab plus ifosfamide,
carboplatin and etoposide (R-ICE), or rituximab plus gemcitabine,
dexamethasone and cisplatin (R-GDP) per the investigators’ choice
before proceeding to high-dose chemotherapy (HDCT) and
hematopoietic stem cell transplant (HSCT). The primary endpoint of
the study was event-free survival, defined as time from
randomization to death from any cause, progressive disease, failure
to achieve complete response or partial response, or start of new
antineoplastic therapy due to efficacy concerns, whichever occurs
first. Complete response rate was a key secondary endpoint. Other
efficacy endpoints included progression-free survival, overall
survival, overall response rate and duration of response.
About PILOT
PILOT (NCT03483103) is a multicenter Phase 2 trial evaluating
Breyanzi as a second-line therapy in adults with relapsed or
refractory large B-cell lymphoma after front-line therapy who are
not considered candidates for hematopoietic stem cell transplant
(HSCT). All enrolled patients have relapsed or refractory large
B-cell lymphoma after treatment with a single line of
chemoimmunotherapy containing an anthracycline and a CD20-targeted
agent. The primary endpoint of the study is overall response rate.
Other efficacy endpoints include complete response rate, duration
of response, progression-free survival, event-free survival and
overall survival.
Important Safety
Information
BOXED WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGIC
TOXICITIES
- Cytokine Release Syndrome (CRS), including fatal or
life-threatening reactions, occurred in patients receiving
BREYANZI. Do not administer BREYANZI to patients with active
infection or inflammatory disorders. Treat severe or
life-threatening CRS with tocilizumab with or without
corticosteroids.
- Neurologic toxicities, including fatal or life-threatening
reactions, occurred in patients receiving BREYANZI, including
concurrently with CRS, after CRS resolution or in the absence of
CRS. Monitor for neurologic events after treatment with BREYANZI.
Provide supportive care and/or corticosteroids as needed.
- BREYANZI is available only through a restricted program under a
Risk Evaluation and Mitigation Strategy (REMS) called the BREYANZI
REMS.
Cytokine Release Syndrome
Cytokine release syndrome (CRS), including fatal or
life-threatening reactions, occurred following treatment with
BREYANZI. Among patients receiving BREYANZI for LBCL (N=418), CRS
occur in 46% (190/418) of patients, including ≥ Grade 3 CRS (Lee
grading system) in 3.1% of patients.
In patients receiving BREYANZI after two or more lines of
therapy for LBCL, CRS occurred in 46% (122/268), including ≥ Grade
3 CRS in 4.1% of patients. One patient had fatal CRS and 2 had
ongoing CRS at time of death. The median time to onset was 5 days
(range: 1 to 15 days). CRS resolved in 98% with a median duration
of 5 days (range: 1 to 17 days).
In patients receiving BREYANZI after one line of therapy for
LBCL, CRS occurred in 45% (68/150), including Grade 3 CRS in 1.3%
of patients. The median time to onset was 4 days (range: 1 to 63
days). CRS resolved in all patients with a median duration of 4
days (range: 1 to 16 days).
The most common manifestations of CRS (≥10%) included fever
(94%), hypotension (42%), tachycardia (28%), chills (23%), hypoxia
(16%), and headache (12%).
Serious events that may be associated with CRS include cardiac
arrhythmias (including atrial fibrillation and ventricular
tachycardia), cardiac arrest, cardiac failure, diffuse alveolar
damage, renal insufficiency, capillary leak syndrome, hypotension,
hypoxia, and hemophagocytic lymphohistiocytosis/macrophage
activation syndrome (HLH/MAS).
Ensure that 2 doses of tocilizumab are available prior to
infusion of BREYANZI.
Of the 418 patients who received BREYANZI for LBCL, 23% received
tocilizumab and/or a corticosteroid for CRS, including 10% who
received tocilizumab only and 2.2% who received corticosteroids
only.
Neurologic Toxicities
Neurologic toxicities that were fatal or life-threatening,
including immune effector cell-associated neurotoxicity syndrome
(ICANS), occurred following treatment with BREYANZI. Serious events
including cerebral edema and seizures occurred with BREYANZI. Fatal
and serious cases of leukoencephalopathy, some attributable to
fludarabine, also occurred.
In patients receiving BREYANZI after two or more lines of
therapy for LBCL, CAR T cell-associated neurologic toxicities
occurred in 35% (95/268), including ≥ Grade 3 in 12% of patients.
Three patients had fatal neurologic toxicity and 7 had ongoing
neurologic toxicity at time of death. The median time to onset of
neurotoxicity was 8 days (range: 1 to 46 days). Neurologic
toxicities resolved in 85% with a median duration of 12 days
(range: 1 to 87 days).
In patients receiving BREYANZI after one line of therapy for
LBCL, CAR T cell-associated neurologic toxicities occurred in 27%
(41/150) of patients, including Grade 3 cases in 7% of patients.
The median time to onset of neurologic toxicities was 8 days
(range: 1 to 63 days). The median duration of neurologic toxicity
was 6 days (range: 1 to 119 days).
In all patients combined receiving BREYANZI for LBCL, neurologic
toxicities occurred in 33% (136/418), including ≥ Grade 3 cases in
10% of patients. The median time to onset was 8 days (range: 1 to
63), with 87% of cases developing by 16 days. Neurologic toxicities
resolved in 85% of patients with a median duration of 11 days
(range: 1 to 119 days). Of patients developing neurotoxicity, 77%
(105/136) also developed CRS.
The most common neurologic toxicities (≥ 5%) included
encephalopathy (20%), tremor (13%), aphasia (8%), headache (6%),
dizziness (6%), and delirium (5%).
CRS and Neurologic Toxicities Monitoring
Monitor patients daily for at least 7 days following BREYANZI
infusion at a REMS-certified healthcare facility for signs and
symptoms of CRS and neurologic toxicities and assess for other
causes of neurological symptoms. Monitor patients for signs and
symptoms of CRS and neurologic toxicities for at least 4 weeks
after infusion and treat promptly. At the first sign of CRS,
institute treatment with supportive care, tocilizumab, or
tocilizumab and corticosteroids as indicated. Manage neurologic
toxicity with supportive care and/or corticosteroid as needed.
Counsel patients to seek immediate medical attention should signs
or symptoms of CRS or neurologic toxicity occur at any time.
BREYANZI REMS
Because of the risk of CRS and neurologic toxicities, BREYANZI
is available only through a restricted program under a Risk
Evaluation and Mitigation Strategy (REMS) called the BREYANZI REMS.
The required components of the BREYANZI REMS are:
- Healthcare facilities that dispense and administer BREYANZI
must be enrolled and comply with the REMS requirements.
- Certified healthcare facilities must have on-site, immediate
access to tocilizumab.
- Ensure that a minimum of 2 doses of tocilizumab are available
for each patient for infusion within 2 hours after BREYANZI
infusion, if needed for treatment of CRS.
- Certified healthcare facilities must ensure that healthcare
providers who prescribe, dispense, or administer BREYANZI are
trained on the management of CRS and neurologic toxicities.
Further information is available at www.BreyanziREMS.com, or
contact Bristol-Myers Squibb at 1-888-423-5436.
Hypersensitivity Reactions
Allergic reactions may occur with the infusion of BREYANZI.
Serious hypersensitivity reactions, including anaphylaxis, may be
due to dimethyl sulfoxide (DMSO).
Serious Infections
Severe infections, including life-threatening or fatal
infections, have occurred in patients after BREYANZI infusion.
In patients receiving BREYANZI for LBCL, infections of any grade
occurred in 36% with Grade 3 or higher infections occurring in 12%
of all patients. Grade 3 or higher infections with an unspecified
pathogen occurred in 7%, bacterial infections occurred in 4.3%,
viral infections in 1.9% and fungal infections in 0.5%.
Febrile neutropenia developed after BREYANZI infusion in 8% of
patients with LBCL. Febrile neutropenia may be concurrent with CRS.
In the event of febrile neutropenia, evaluate for infection and
manage with broad spectrum antibiotics, fluids, and other
supportive care as medically indicated.
Monitor patients for signs and symptoms of infection before and
after BREYANZI administration and treat appropriately. Administer
prophylactic antimicrobials according to standard institutional
guidelines.
Avoid administration of BREYANZI in patients with clinically
significant active systemic infections.
Viral reactivation: Hepatitis B virus (HBV) reactivation, in
some cases resulting in fulminant hepatitis, hepatic failure, and
death, can occur in patients treated with drugs directed against B
cells.
In patients who received BREYANZI for LBCL, 15 of the 16
patients with a prior history of HBV were treated with concurrent
antiviral suppressive therapy. Perform screening for HBV, HCV, and
HIV in accordance with clinical guidelines before collection of
cells for manufacturing. In patients with prior history of HBV,
consider concurrent antiviral suppressive therapy to prevent HBV
reactivation per standard guidelines.
Prolonged Cytopenias
Patients may exhibit cytopenias not resolved for several weeks
following lymphodepleting chemotherapy and BREYANZI infusion.
Grade 3 or higher cytopenias persisted at Day 29 following
BREYANZI infusion in 36% of patients with LBCL, and included
thrombocytopenia in 28%, neutropenia in 21%, and anemia in 6%.
Monitor complete blood counts prior to and after BREYANZI
administration.
Hypogammaglobulinemia
B-cell aplasia and hypogammaglobulinemia can occur in patients
receiving treatment with BREYANZI.
In patients receiving BREYANZI for LBCL, hypogammaglobulinemia
was reported as an adverse reaction in 11% of patients.
Hypogammaglobulinemia, either as an adverse reaction or laboratory
IgG level below 500 mg/dL after infusion, was reported in 28% of
patients.
Monitor immunoglobulin levels after treatment with BREYANZI and
manage using infection precautions, antibiotic prophylaxis, and
immunoglobulin replacement as clinically indicated.
Live vaccines: The safety of immunization with live viral
vaccines during or following BREYANZI treatment has not been
studied. Vaccination with live virus vaccines is not recommended
for at least 6 weeks prior to the start of lymphodepleting
chemotherapy, during BREYANZI treatment, and until immune recovery
following treatment with BREYANZI.
Secondary Malignancies
Patients treated with BREYANZI may develop secondary
malignancies. Monitor lifelong for secondary malignancies. In the
event that a secondary malignancy occurs, contact Bristol-Myers
Squibb at 1-888-805-4555 for reporting and to obtain instructions
on collection of patient samples for testing.
Effects on Ability to Drive and Use Machines
Due to the potential for neurologic events, including altered
mental status or seizures, patients receiving BREYANZI are at risk
for developing altered or decreased consciousness or impaired
coordination in the 8 weeks following BREYANZI administration.
Advise patients to refrain from driving and engaging in hazardous
occupations or activities, such as operating heavy or potentially
dangerous machinery, for at least 8 weeks.
Adverse Reactions
The most common nonlaboratory adverse reactions (incidence ≥
30%) are fever, CRS, fatigue, musculoskeletal pain, and nausea.
The most common Grade 3-4 laboratory abnormalities (≥ 30%)
include lymphocyte count decrease, neutrophil count decrease,
platelet count decrease, hemoglobin decrease.
Please see full Prescribing Information, including Boxed
WARNINGS and Medication Guide.
Bristol Myers Squibb: Creating a Better
Future for People with Cancer
Bristol Myers Squibb is inspired by a single vision—transforming
patients’ lives through science. The goal of the company’s cancer
research is to deliver medicines that offer each patient a better,
healthier life and to make cure a possibility. Building on a legacy
across a broad range of cancers that have changed survival
expectations for many, Bristol Myers Squibb researchers are
exploring new frontiers in personalized medicine, and through
innovative digital platforms, are turning data into insights that
sharpen their focus. Deep scientific expertise, cutting-edge
capabilities and discovery platforms enable the company to look at
cancer from every angle. Cancer can have a relentless grasp on many
parts of a patient’s life, and Bristol Myers Squibb is committed to
taking actions to address all aspects of care, from diagnosis to
survivorship. Because as a leader in cancer care, Bristol Myers
Squibb is working to empower all people with cancer to have a
better future.
Learn more about the science behind cell therapy and ongoing
research at Bristol Myers Squibb here.
About Bristol Myers
Squibb
Bristol Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube, Facebook and
Instagram.
Bristol Myers Squibb Cautionary
Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
regarding, among other things, the research, development and
commercialization of pharmaceutical products. All statements that
are not statements of historical facts are, or may be deemed to be,
forward-looking statements. Such forward-looking statements are
based on current expectations and projections about our future
financial results, goals, plans and objectives and involve inherent
risks, assumptions and uncertainties, including internal or
external factors that could delay, divert or change any of them in
the next several years, that are difficult to predict, may be
beyond our control and could cause our future financial results,
goals, plans and objectives to differ materially from those
expressed in, or implied by, the statements. These risks,
assumptions, uncertainties and other factors include, among others,
whether Breyanzi® (lisocabtagene maraleucel), for the indication
described in this release, will be commercially successful, any
marketing approvals, if granted, may have significant limitations
on their use, and that continued approval of such product candidate
for such indication described in this release may be contingent
upon verification and description of clinical benefit in
confirmatory trials. No forward-looking statement can be
guaranteed. Forward-looking statements in this press release should
be evaluated together with the many risks and uncertainties that
affect Bristol Myers Squibb’s business and market, particularly
those identified in the cautionary statement and risk factors
discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for
the year ended December 31, 2021, as updated by our subsequent
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and
other filings with the Securities and Exchange Commission. The
forward-looking statements included in this document are made only
as of the date of this document and except as otherwise required by
applicable law, Bristol Myers Squibb undertakes no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events, changed circumstances
or otherwise.
corporatefinancial-news
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220427005982/en/
Bristol Myers Squibb Media Inquiries:
media@bms.com Nikki Copas nikki.copas@bms.com Investors:
investor.relations@bms.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024